ArticleJournal of medical ethics2020
Intergenerational monitoring in clinical trials of germline gene editing.
Article in Journal of medical ethics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine.Pediatric research · 2026Review
- Which religious and personal characteristics predict attitudes toward gene editing? Findings from a survey of 4,939 adults in the U.S.Journal of community genetics · 2026Article
- Modular Ontologies for Genetically Modified People and their Bioethical Implications.Nanoethics · 2024Article
- Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic.Medicine, health care, and philosophy · 2023Article
- Future of global regulation of human genome editing: a South African perspective on the WHO Draft Governance Framework on Human Genome Editing.Journal of medical ethics · 2022Article
- Revising, Correcting, and Transferring Genes.The American journal of bioethics : AJOB · 2020Article
- Days of Future Past: Reply to Open Peer Commentaries on "Revising, Correcting, and Transferring Genes".The American journal of bioethics : AJOB · 2020Article
- Responsible Translational Pathways for Germline Gene Editing?Current stem cell reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Design of clinical trials for germline gene editing stretches current accepted standards for human subjects research. Among the challenges involved is a set of issues concerning
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.